Last reviewed · How we verify

Livzon Pharmaceutical Group Inc. — Portfolio Competitive Intelligence Brief

Livzon Pharmaceutical Group Inc. pipeline: 2 marketed, 0 filed, 4 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 4 Phase 3 3 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Esoprazole Esoprazole marketed Other
amoxicillin and clarithromycin amoxicillin and clarithromycin marketed
Ilaprazole tablet Ilaprazole tablet phase 3 Proton pump inhibitor (PPI) H+/K+-ATPase (proton pump) Gastroenterology
JP-1366 simulation tablets JP-1366 simulation tablets phase 3
LZM012 LZM012 phase 3
SARS-Cov-2 Vaccine Inactivated SARS-Cov-2 Vaccine Inactivated phase 3 Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes
  2. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  3. Baxter · 1 shared drug class
  4. Ain Shams University · 1 shared drug class
  5. AstraZeneca · 1 shared drug class
  6. AstraZeneca (originally Astra AB) · 1 shared drug class
  7. Ace Cells Lab Limited · 1 shared drug class
  8. Abbott · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Livzon Pharmaceutical Group Inc.:

Cite this brief

Drug Landscape (2026). Livzon Pharmaceutical Group Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/livzon-pharmaceutical-group-inc. Accessed 2026-05-17.

Related